Hookipa Pharma (NASDAQ:HOOK) Receives Buy Rating from Royal Bank of Canada

Royal Bank of Canada reissued their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a research note released on Wednesday, AnalystRatings.com reports. Royal Bank of Canada currently has a $23.00 price objective on the stock.

Several other research firms have also issued reports on HOOK. Bank of America initiated coverage on shares of Hookipa Pharma in a research report on Monday, May 13th. They issued a buy rating and a $17.00 price target on the stock. Zacks Investment Research downgraded shares of Hookipa Pharma from a hold rating to a sell rating in a report on Wednesday, July 17th. Svb Leerink initiated coverage on shares of Hookipa Pharma in a report on Monday, May 13th. They set an outperform rating and a $20.00 price target for the company. Finally, Leerink Swann initiated coverage on shares of Hookipa Pharma in a report on Monday, May 13th. They set an outperform rating and a $20.00 price target for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $20.00.

HOOK traded down $0.08 during trading on Wednesday, hitting $6.92. The stock had a trading volume of 2,373 shares, compared to its average volume of 101,272. Hookipa Pharma has a 12 month low of $6.06 and a 12 month high of $14.76. The company has a 50 day simple moving average of $6.97.



Hookipa Pharma (NASDAQ:HOOK) last announced its earnings results on Monday, May 20th. The company reported ($9.27) EPS for the quarter, missing the consensus estimate of ($0.42) by ($8.85). The company had revenue of $2.24 million for the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities research analysts forecast that Hookipa Pharma will post -2.14 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new position in Hookipa Pharma during the second quarter valued at approximately $40,000. Northern Trust Corp bought a new stake in Hookipa Pharma during the second quarter worth $72,000. Morgan Stanley bought a new stake in Hookipa Pharma during the second quarter worth $99,000. Vanguard Group Inc. bought a new stake in Hookipa Pharma during the second quarter worth $538,000. Finally, BlackRock Inc. bought a new stake in Hookipa Pharma during the second quarter worth $737,000.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Read More: Stock Symbol

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.